Health  Vol.2 No.7 , July 2010
PET in uterine malignancies
ABSTRACT
Positron Emission Tomography (PET) or integrated PET/Computed Tomography (PET/CT) with 18F-Fluoro-Deoxy-Glucose (18F-FDG) is a functional imaging modality, useful in the characterization of undetermined morphological findings, and in the staging/re-staging of a large number of malignancies. Although its use in uterine malignancies has been poorly investigated, in recent years the employment of this technique has constantly increased. In this review, we evaluate the role of PET (/CT) with 18FFDG in uterine malignancies (cervical and endometrial cancers as well as uterine sarcomas), underlying its advantages and discussing its limitations. Metabolic and anatomic information given by PET/CT with 18F-FDG could be useful in the evaluation of local and distant disease involvement at the staging, in the detection of disease recurrence, and in the evaluation of the response after chemotherapy and/or radio-therapy.

Cite this paper
nullPirro, V. , Skanjeti, A. and Pelosi, E. (2010) PET in uterine malignancies. Health, 2, 652-660. doi: 10.4236/health.2010.27099.
References
[1]   Tatsumi M, Cohade C, Bristow R.E. and Wahl R.L. (2009) Imaging uterine cervical cancer with FDG-PET/ CT: Direct comparison with PET. Molecular Imaging and Biology, 11(4), 229-235.

[2]   National Cancer Institute, Cervical Cancer, Bethesda (MD). www.cancer.gov/cancertopics/types /cervical

[3]   Arbyn, M., Raifu, A.O. and Ferlay, J. (2007) Burden of cervical cancer in Europe. Annals of Oncology, 18(10), 1708-1715.

[4]   Brooks, R.A, Rader, J.S., Dehdashti, F., Mutch, D.G., Powell, M.A., Thaker, P.H., Siegel, B.A. and Grigsby, P.W. (2009) Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecologic Oncolology, 112(1), 104-109.

[5]   Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J. and Thun, M.J. (2009) Cancer statistics. CA: A Cancer Journal for Clinicians, 59(4), 225-249.

[6]   Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T. and Thun, M.J. (2008) Cancer statistics, 2008. CA: A Cancer Journal for Clinicians, 58(2), 71-96.

[7]   Loft, A., Berthelsen, A.K., Roed, H., Ottosen, C., Lundwall, L., Knudsen, J., Nedergaard, L., H?jgaard, L. and Engelholm, S.A. (2007) The diagnostic value of PET/CT scanning in patients with cervical cancer: A prospective study. Gynecologic Oncolology, 106(1), 29-34.

[8]   Pecorelli, S., Benedet, J.L., Creasman, W.T. and Shepherd J.H. (1999) FIGO staging of gynecologic cancer. 1994-1997 FIGO committee on gynecologic oncology. international federation of gynecology and obstetrics. International Journal of Gynaecology and Obstetrics, 65(3), 243-269.

[9]   Park, W., Park, Y.J., Huh. S.J., Kim, B.G., Bae, D.S., Lee J., Kim, B.H., Choi, J.Y., Ahn, Y.C. and Lim, D.H. (2005) The usefulness of MRI and PET imaging for the detection of parametrial involvement and lymph node metastasis in patients with cervical cancer. Japanese Journal of Clinical Oncology, 35(5), 260-264.

[10]   Grigsby, P.W. and Herzog, T.J. (2001) Current management of patients with invasive cervical carcinoma. Clinical Obstetrics and Gynecology, 44(3), 531-537.

[11]   Nicolet, V., Carignan, L., Bourdon, F. and Prosmanne, O. (2000) MR imaging of cervical carcinoma: a practical staging approach. Radiographics, 20(6), 1539-1549.

[12]   Kumar, R. and Dadparvar, S. (2007) 18F-Fluoro-2-deoxy-D-glucose-Positron Emission Tomography (PET)/ PET-Computed Tomography in carcinoma of the cervix. Cancer, 110(8), 1650-1653.

[13]   Chung, H.H., Kim, S.K., Kim, T.H., Lee, S., Kang, K.W., Kim, J.Y. and Park, S.Y. (2006) Clinical impact of 18F-FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: From diagnosis to prognosis. Gynecologic Oncolology, 103(1), 165-170.

[14]   Ryu, S.Y., Kim, M.H., Choi, S.C., Choi, C.W. and Lee, K.H. (2003) Detection of early recurrence with 18F-18F- FDG PET in patients with cervical cancer. Journal of Nuclear Medicine, 44(3), 347-352.

[15]   Harry, V.N. (2010) Novel imaging techniques as response biomarkers in cervical cancer. Gynecologic Oncolology, 116(2), 253-261.

[16]   Lerman, H., Metser, U., Grisaru, D., Fishman, A., Lievshitz, G. and Even-Sapir, E. (2004) Normal and abnormal 18F-18F-FDG endometrial and ovarian uptake in pre- and post- menopausal patients: Assessment by PET/ CT. Journal of Nuclear Medicine, 45(2), 266-271.

[17]   Kidd, E.A., Siegel, B.A., Dejdashti, F. and Grigsby, P.W. (2007) The standardized uptake value for F18-Fluorodeoxy- glucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer, 110(8), 1738-1744.

[18]   Xue, F., Lin, L.L., Dehdashti, F., Miller, T.R., Siegel, B.A. and Grigsby, P.W. (2006) F18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecologic Oncolology, 101(1), 146-151.

[19]   Nishiyama, Y., Yamamoto, Y., Kanenishi, K., Ohno, M., Hata, T., Kushida, Y., Haba, R. and Ohkawa, M. (2008) Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 35(2), 287-295.

[20]   Yoshida, Y., Kurokawa, T., Kawahara, K., Yagihara, A., Tsuchida, T., Okazawa, H., Fujibayashi, Y., Yonekura, Y. and Kotsuji, F. (2004) Metabolic monitoring of advanced uterine cervical cancer neoadjuvant chemotherapy by using [F-18]-Fluorodeoxyglucose positron emission tomography: Preliminary results in three patients. Gynecologic Oncolology, 95(3), 597-602.

[21]   Kidd, E.A., Spencer, C.R., Huettner, P.C., Siegel, B.A., Dehdashti, F., Rader, J.S. and Grigsby, P.W. (2009) Cervical cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake. Cancer, 115(15), 3548- 3554.

[22]   Lee, Y.Y., Choi, C.H., Kim, C.J., Kang, H., Kim, T.J., Lee, J.W., Lee, J.H., Bae, D.S. and Kim, B.G. (2009) The prognostic significance of the SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) of the cervical tumor in PET imaging for early cervical cancer: Preliminary results. Gynecologic Oncolology, 115(1), 65-68.

[23]   Kim, S.K., Choi, H.J., Park, S.Y., Lee, H.Y., Seo, S.S., Yoo, C.W., Jung, D.C., Kang, S. and Cho, K.S. (2009) Additional value of MR/PET fusion compared with PET/CT in the detection of lymph node metastases in cervical cancer patients. European Journal of Cancer, 45(12), 2103-2109.

[24]   Selman, T.J., Mann, C., Zamora, J., Appleyard, T.L. and Khan, K. (2008) Diagnostic accuracy of tests for lymph node status in primary cervical cancer: A systematic review and a metanalysis. Canadian Medical Association Journal, 178(7), 855-862.

[25]   Yildirim, Y., Sehirali, S., Avci, M.E., Yilmaz, C., Ertopcu K., Tinar, S., Duman, Y. and Sayhan, S. (2008) Integrated PET/CT for the evaluation of paraaortic nodal metastasis in locally advanced cervical cancer patients with negative conventional CT findings. Gynecologic Oncolology, 108(1), 154-159.

[26]   Havrilesky, L.J., Kulasingam, S.L., Matchar, D.B. and Myers, E.R. (2005) 18F-FDG-PET for management of cervical and ovarian cancer. Gynecologic Oncolology, 97(1), 183-191.

[27]   Husain, A., Akhurst, T., Larson, S., Alektiar, K., Barakat, R.R. and Chi, D.S. (2007) A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18F-FDG PET) in identifying sites of metastasis prior to pelvic exenteration. Gynecologic Oncolology, 106(1), 177-180.

[28]   Nakamoto, Y., Saga, T. and Fujii, S. (2005) Positron emission tomography application for gynecologic tumors. International Journal of Gynecological Cancer, 15(5), 701-709.

[29]   Roh, J.W., Seo, S.S., Lee, S., Kang, K.W., Kim, S.K., Sim, J.S., Kim, J.Y., Hong, E.K., Cho, D.S., Lee, J.S. and Park, S.Y. (2005) Role of positron emission tomography in pretreatment lymph node staging of uterine cervical cancer: A prospective surgicopathologic correlation study. European Journal of Cancer, 41(14), 2086-2092.

[30]   Unger, J.B., Lilien, D.L., Caldito, G., Ivy, J.J., Charrier, A. and Bellaire, B. (2007) The prognostic value of pretreatment 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography scan in women with cervical cancer. International Journal of Gynecological Cancer, 17(5), 1062-1067.

[31]   Wright, J.D., Dehdashti, F., Herzog, T.J., Mutch, D.G., Huettner, P.C., Rader, J.S., Gibb, R.K., Powell, M.A., Gao, F., Siegel, B.A. and Grigsby, P.W. (2005) Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer, 104(11), 2484-2491.

[32]   Rezvani, M. and Shaaban, A. (2009) Imaging of cervical pathology. Clinical Obstetrics and Gynecology, 52(1), 94-111.

[33]   Sironi, S., Buda, A., Picchio, M., Perego, P., Moreni, R., Pellegrino, A., Colombo, M., Mangioni, C., Messa, C. and Fazio, F. (2006) Lymph node metastasis in patients with clinical early-stage cervical cancer: Detection with integrated 18F-FDG PET/CT. Radiology, 238(1), 272- 279.

[34]   Choi, H.J., Roh, J.W., Seo, S.S., Lee, S., Kim, J.Y., Kim, S.K., Kang, K.W., Lee, J.S., Jeong, J.Y and Park, S.Y. (2006) Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/com- puted tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma: A prospective study. Cancer, 106(4), 914- 922.

[35]   Chao, A., Ho, K.C., Wang, C.C., Cheng, H.H., Lin, G., Yen, T.C. and Lai, C.H. (2008) Positron emission tomography in evaluating the feasibility of curative intent in cervical cancer patients with limited distant lymph node metastasis. Gynecologic Oncology, 110(2), 172-178.

[36]   Yen, T.C., See, L.C., Lai, C.H., Tsai, C.S, Chao, A., Hsueh, S., Hong, J.H., Chang, T.C. and Ng, K.K. (2008) Standardized up-take value in paraaortic lymph nodes is a significant prognostic factor in patients with primary advanced squamous cervical cancer. European Journal of Nuclear Medicine and Molecular Imaging, 35(3), 493- 501.

[37]   Amit, A., Beck, D., Lowenstein, L., Lavie, O., Bar shalom, R., Kedar, Z. and Israel, O. (2006) The role of hybrid PET/CT in the evaluation of patients with cervical cancer. Gynecologic Oncology, 100(1), 65-69.

[38]   Chou, H.H., Chang, T.C., Yen, T.C., Ng, K.K., Hsueh, S., Ya Ma, S., Chang, C.J., Huang, H.J., Chao, A., Wu, T.I., Jung, S.M., Lin, C.T., Huang, K.G. and Lai, C.H. (2006) Low value of [18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in primary staging of early stage cervical cancer before radical hysterectomy. Journal of Clinical Oncology, 24(1), 123-128.

[39]   Boughanim, M., Leboulleux, S., Rey, A., Pham, C.T., Zafrani, Y., Duvillard, P,, Lumbroso, J., Haie-Meder, C., Schlumberger, M. and Morice, P. (2008) Histologic results of paraaortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F] Fluorodeoxy-glucose positron emission tomography scans in the paraaortic area. Journal of Clinical Oncology, 26(15), 2558- 2561.

[40]   Kitajima, K., Murakami, K., Yamasaki, E., Kaji, Y. and Sugimura, K. (2009) Accuracy of integrated FDG-PET/ contrast-enhanced CT in detecting pelvic and paraaortic lymph node metastasis in patients with uterine cancer. European Radiology, 19(6), 1529-1536.

[41]   Grosu, A.L., Piert, M., Weber, W., Jeremic, B., Piccio, M., Schratzenstaller, U., Zimmermann, F.B., Schwaiger, M. and Molls, M. (2005) Positron Emission Tomography for radiation treatment planning. Strahlentherapie und Onko- logie, 181(8), 483-499.

[42]   Gold, M.A., Tian, C., Whitney, C.W., Rose, P.G. and Lanciano, R. (2008) Surgical versus radiographic determination of paraaortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma: A Gynecologic Oncology Group Study. Cancer, 112(9), 1954-1963.

[43]   Dolezelova, H., Slampa, P., Ondrova, B., Gombosova, J., Sovadinova, S., Novotny, T., Bolcak, K., Ruzickova, J., Hynkova, L. and Forbelska, M. (2008) The impact of PET with 18FDG in radiotherapy treatment planning and in the prediction in patients with cervix carcinoma: results of pilot study. Neoplasma, 55(5), 437-441.

[44]   Boughanim, M., Leboulleux, S., Rey, A., Pham, C.T., Zafrani, Y., Duvillard, P., Lumbroso, J., Haie-Meder, C., Schlumberger, M. and Morice, P. (2008) Histologic results of paraaortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F] fluorodeoxyglucose positron emission tomography scans in the paraaortic area. Journal of Clinical Oncology, 26(15), 2558-2561.

[45]   Regione Emilia Romagna. 18F-FDG-PET in oncologia. Criteri per un uso appropriato. Published in 2006.

[46]   Chao, A., Ho, K.C., Wang, C.C., Cheng, H.H., Lin, G., Yen, T.C. and Lai, C.H. (2008) Positron emission tomography in evaluating the feasibility of curative intent in cervical cancer patients with limited distant lymph node metastases. Gynecologic Oncology, 110(2), 172-178.

[47]   Lin, C.T., Yen, T.C., Chang, T.C., Ng, K.K., Tsai, C.S., Ho, K.C. and Lai, C.H. (2006) Role of [18F] fluoro-2- deoxy-D-glucose positron emission tomography in re-recurrent cervical cancer. International Journal of Gynecological Cancer, 16(6), 1994-2003.

[48]   Esthappan, J., Mutic, S., Malyapa, R.S., Grigsby, P.W., Zoberi, I., Dehdashti, F., Miller, T.R., Bosch, W.R. and Low, D.A. (2004) Treatment planning guidelines regarding the use of CT/PET-guided IMRT for cervical carcinoma with positive paraaortic lymph nodes. International Journal of Radiation Oncology, Biology, Physics, 58(4), 1289-1297.

[49]   Esthappan, J., Chaudhari, S., Santanam, L., Mutic, S., Olsen, J., MacDonald, D.M., Low, D.A., Singh, A.K. and Grigsby, P.W. (2008) Prospective clinical trial of Positron Emission Tomography/Computed Tomography image- guided intensity-modulated radiation therapy for cervical carcinoma with positive paraaortic lymph nodes. International Journal of Radiation Oncology, Biology, Physics, 72(4), 1134-1139.

[50]   Lin, L.L., Mutic, S., low, D., LaForest, R., Vicic, M., Zoberi, I., Miller, T.R. and Grigsby, P.W. (2007) Adaptive brachytherapy treatment planning for cervical cancer using 18F-FDG-PET. Journal of Radiation Oncology, Biology, Physics, 67(1), 91-96.

[51]   Kitajima, K., Murakami, K., Yamasaki, E., Hagiwara, S., Fukasawa, I., Inaba, N., Kaji, Y. and Sugimura, K. (2008) Performance of 18F-FDG-PET/CT in the diagnosis of re- current endometrial cancer. Annals of Nuclear Medicine, 22(2), 103-109.

[52]   Grisaru, D., Almog, B., Levine, C., Metser, U., Fishman A., Lerman, H., Lessing, J.B. and Even-Sapir, E. (2004) The diagnostic accuracy of 18F-fluorodeoxyglucose PET/ CT in patients with gynecological malignancies. Gynecologic Oncoloy, 94(3), 680-684.

[53]   van der Veldt, A.A., Buist, M.R., van Baal, M.W., Comans, E.F., Hoekstra, O.S. and Molthoff, C.F. (2008) Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: Impact of 18F-FDG PET. Journal of Nuclear Medicine, 49(12), 1936-1943.

[54]   Bjurberg, M., Kjellen, E., Ohlsson, T., Ridderheim, M. and Brun, E. (2007) 18F-FDG-PET in cervical cancer: staging, re-stagting and follow up. Acta Obstetricia et Gynecologica, 86(11), 1385-1391.

[55]   Schwarz, J.K., Siegel, B.A., Dehdashti, F. and Grigsby, P.W. (2007) Association of posttherapy positron emission tomogramphy with tumor response and survival in cervical carcinoma. Journal of the American Medical Association, 289(19), 2289-2295.

[56]   Schwarz, J.K., Grigsby, P.W., Dehdashti, F. and Delbeke, D. (2009) The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. Journal of Nuclear Medicine, 50 (Suppl 1), 64S-73S.

[57]   Bray, F., Dos, S.S.I., Moller, H. and Weiderpass, E. (2005) Endometrial cancer incidence trends in Europe: Underlying determinants and prospects for prevention. Cancer Epidemiology, Biomarkers & Prevention, 14(5), 1132- 1142.

[58]   Jemal, A., Tiwari, R.C., Murray, T., Ghafoor, A., Samuel, A., Ward, E., Feuer, E.J. and Thun, M.J. (2004) American Cancer Society. Cancer Statistics, 2004. CA: A Cancer Journal for Clinicians, 54(1), 8-29.

[59]   Torizuka, T., Nakamura, F., Takekuma, M., Toshihiko, K., Ogusu, T., Yoshikawa, E., Okada, H., Maeda, M. and Ouchi, Y. (2006) 18F-FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer. Nuclear Medicine Communications, 27(6), 481- 487.

[60]   Chao, A., Chang, T.C., Ng, K.K., Hsueh, S., Huang, H.J., Chou, H.H., Tsai, C.S., Yen, T.C., Wu, T.I. and Lai, C.H. (2006) 18F-FDG PET in the management of endometrial cancer. European Journal of Nuclear Medicine and Molecular Imaging, 33(1), 36-44.

[61]   Suzuki, R., Miyagi, E., Takahashi, N., Sukegawa, A., Suzuki, A., Koike, I., Sugiura, K., Okamoto, N., Inoue, T. and Hirahara, F. (2007) Validity of positron emission tomography using fluoro-2-deoxyglucose for the preoperative evaluation of endometrial cancer. International Journal of Gynecological Cancer, 17(1), 890-896.

[62]   Horowitz, N.S., Dehdashti, F., Herzog, T.J., Rader, J.S., Powell, M.A., Gibb, R.K., Grigsby, P.W., Siegel, B.A, Mutch, D.G. (2004) Prospective evaluation of 18F-FDG- PET for detecting pelvic and para-aortic lymphnode metastasis in uterine corpus cancer. Gynecologic Oncology, 95(3), 546-551.

[63]   Signorelli, M., Guerra, L., Buda, A., Picchio, M., Mangili G., Dell’Anna, T., Sironi, S. and Messa, C. (2009) Role of the integrated FDG PET/CT in the surgical management of patients with high risk clinical early stage endometrial cancer: Detection of pelvic nodal metastases. Gynecologic Oncology, 115(2), 231-235.

[64]   ASTEC study group, Kitchener, H., Swart, A.M., Qian, Q., Amos, C. and Parmar, M.K. (2009) Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): A randomised study. Lancet, 373(9658), 125-136.

[65]   Benedetti, P. P., Basile, S., Maneschi, F., Alberto, L. A., Signorelli, M., Scambia, G., Angioli, R., Tateo, S., Mangili, G., Katsaros, D., Garozzo, G., Campagnutta, E., Donadello, N., Greggi, S., Melpignano, M., Raspagliesi, F., Ragni, N., Cormio, G., Grassi, R., Franchi, M., Giannarelli, D., Fossati, R., Torri, V., Amoroso, M., Crocè, C. and Man- gioni, C. (2008) Systematic pelvic lympha-denectomy vs. no lymphad-enectomy in early-stage endometrial carcino- ma: randomized clinical trial. Journal of the N

[66]   Park, J.Y., Kim, E.N., Suh, D.S., Kim, J.H., Kim, Y.M., Kim, Y.T. and Nam, J.H. (2008) Comparison of the validity of magnetic resonance imaging and positron emission tomography/ computed tomography in the preoperative evaluation of patients with uterine corpus cancer. Gynecologic Oncology, 108(3), 486-492.

[67]   Kitajima, K., Murakami, K., Yamasaki, E., Fukasawa, I., Inaba, N., Kaji, Y. and Sugimura, K. (2008) Accuracy of 18F-FDG PET/CT in detecting pelvic and paraaortic lymph node metastasis in patients with endometrial can- cer. American Journal of Roentgenology, 190(6), 1652- 1658.

[68]   Inubashiri, E., Hata, K., Kanenishi, K., Shiota, A., Ohno, M., Yamamoto, Y., Nishiyama, Y., Ohkawa, M. and Hata, T. (2009) Positron emission tomography with the glucose analog [F]-fluoro-2-deoxy-D-glucose for evaluating pelvic lymph node metastasis in uterine corpus cancer: Comparison with CT and MRI findings. The Journal of Obstetrics and Gynaecology Research, 35(1), 26-34.

[69]   Sironi, S., Picchio, M., Landoni, C., Galimberti, S., Signorelli, M., Bettinardi, V., Perego, P., Mangioni, C., Messa, C. and Fazio, F. (2007) Post-therapy surveillance of patients with uterine cancers: Value of integrated 18F-FDG-PET/CT in the detection of recurrence. European Journal of Nuclear Medicine and Molecular Imaging, 34(4), 472-479.

[70]   Kitajima, K., Murakami, K., Yamasaki, E., Hagiwara, S., Fukasawa, I., Inaba, N., Kaji, Y. and Sugimura, K. (2008) Performance of 18F-FDG-PET/CT in the diagnosis of recurrent endometrial cancer. Annals of Nuclear Medicine, 22(2), 103-109.

[71]   Ho, K.C., Lai, C.H., Wu, T.I., Ng, K.K., Yen, T.C., Lin, G., Chang, T.C., Wang, C.C., Hsueh, S. and Huang, H.J. (2008) 18F-fluoro-deoxyglucose positron emission tomography in uterine carcinosarcoma. European Journal of Nuclear Medicine and Molecular Imaging, 35(3), 484-492.

[72]   Murakami, M., Tsukada, H., Shida, M., Watanabe, M., Maeda, H., Koido, S., Hirasawa, T., Muramatsu, T., Miyamoto, T., Nasu, S., Yasuda, S., Kajiwara, H. and Yasuda, Ide, M. (2006) Whole-body positron emission tomography with F18 fluorodeoxyglucose for the detection of recurrence in uterine sarcomas. International journal of gynecological Cancer, 16(2), 854-860.

[73]   Bastiaannet, E., Groen, H., Jager, P.L., Cobben, D.C., van der Graaf, W.T., Vaalburg, W. and Hoekstra, H.J. (2004) The value of 18F-FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treatment Reviews, 30(1), 83-101.

[74]   Rebollo, A.A.C., Ramos, F.C., Bellon G.M.E., Cabello G. D., Gallego P.M, Rodriguez, F.A. and Llamas E.J.M. (2007) Positron Emission Tomography with 18F-fluoro- deoxyglucose in patients with uterine sarcoma. Revista Espa?ola de Medicina Nuclear, 26(4), 189-195.

[75]   Nugent, E.K., Zighelboim, I., Case, A.S., Gao, F., Thaker, P.H., Rader, J.S., Mutch, D.G. and Massad, L.S. (2009) The value of perioperative imaging in patients with uterine sarcomas. Gynecologic Oncology, 115(1), 37-40.

[76]   Ho, K.C., Lai, C.H., Wu, T.I., Ng. K.K., Yen. T.C., Lin, G., Chang, T.C., Wang. C.C., Hsueh, S. and Huang, H.J. (2008) 18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma. European Journal of Nuclear Medicine and Molecular Imaging, 35(3), 484- 92.

[77]   Park, J.Y., Kim, E.N., Kim, D.Y., Suh, D.S., Kim, J.H., Kim, Y.M., Kim, Y.T. and Nam, J.H. (2008) Role of PET or PET/CT in the post-therapy surveillance of uterine sarcoma. Gynecologic Oncology, 109(2), 255-262.

[78]   Kizer, N.T., Zighelboim, I., Case, A.S., Dewdney, S.B., Thaker, P.H. and Massad, L.S. (2009) The role of PET/CT in the management of patients with cervical cancer: Practice patterns of the members of the Society of Gynecologic Oncologists. Gynecologic Oncology, 114(2), 310-314.

 
 
Top